The haemolysis caused by various types of liposomes was measured after incubation of liposomes with human red blood cell (erythrocyte) suspension. Liposomes composed of phospholipids and containing or not arsonolipids (arsonoliposomes) were tested. In some cases liposomes that were coated with polyethylene glycol (MW 2000), which were formulated by including 8 mol% DSPE-PEG 2000 in their lipid membrane, were used. Multilamellar vesicles were prepared by the thin film hydration technique (conventional liposomes) or by the one-step technique (arsonoliposomes). Sonicated vesicles were produced by probe sonication of the initial liposome preparations. Phospholipid concentration in the liposome dispersions were measured by the Stewart assay, and adjusted accordingly. Haemolysis was measured after incubating 100 l of liposome dispersions with 900 l of red blood cell suspension (blood) for 1 h. The results reveal that the haemolysis caused, when liposomes are incubated in blood at concentrations below 0.16 mg (lipid)/ml (blood), was minimum. Only in case of Pegylated arsonoliposomes, significant haemolysis percents were observed. At higher lipid concentrations, 0.38 or 0.6 mg/ml, the haemolysis caused by arsonoliposomes was substantially increased, even in the cases of non-Pegylated arsonoliposomes. In most cases, especially when arsonolipid-containing liposomes were evaluated, vesicle size also had considerable effect on vesicle-induced haemolysis. Nevertheless, at concentrations which are relevant with liposomal drug administration in humans, all formulations tested demonstrated negligible haemolysis.
INTRODUCTION
The biocompatibility and haemocompatibility of nanoparticulate drug carriers has not been adequately considered, as recently reviewed. 1 When nanoparticles or liposomes are developed as systems to deliver drugs to specific cell types after circulating for long time periods in the bloodstream, their compatibility with blood is of increased importance. Haemolysis studies should be performed during the development of such nanoparticulate drug formulations. Factors, such as nanoparticle size, surface properties and concentration of the nanoparticles brought in contact with blood erythrocytes, should be considered, during the * Author to whom correspondence should be addressed. assessment of their toxicity towards blood. However, to our best knowledge, such studies have not been performed, in systematic ways.
In our study, we focused on liposomes and arsonoliposomes (liposomes which contain arsonolipids) ( Fig. 1) in their lipid membranes. These have been shown to have interesting anticancer and anti parasitic activities, worthy of in vivo exploration. 2 3 In order to use arsonoliposomes as anticancer agents, alone or in combination with other chemotherapeutics (that may be incorporated or encapsulated in the arsonolipid carriers), their toxicity towards erythrocytes should be evaluated, especially at concentrations which are relevant with therapeutic applications of drug carrier systems. This is in fact required in the case of arsonoliposomes, due to the fact that different methods of arsenic exposure have been reported to result in erythrocyte toxicity in humans. In fact, it is known that arsenic enters the human body through ingestion, inhalation or skin absorption and most of the ingested and inhaled arsenic is absorbed into the bloodstream through gastrointestinal tract and lungs. 4 Erythrocyte is the first target that arsenic compounds attack in the body after systemic absorption. Clinical experience is consistent with decreased hematocrit and intravascular haemolysis. 4 However, changes in erythrocytes deformability due to arsenic exposure under in vitro conditions, have also been demonstrated. 5 Recently it has been proved that arsenic exposure results in the enhancement of phosphatidylserine exposure, ceramide formation and hemoglobin release from erythrocytes. 6 7 Herein we studied the haemolysis caused by a number of different liposome types. Conventional liposomes (consisted of phospholipids) and arsonoliposomes (containing arsonolipids in their lipid membranes), with different lipid compositions were initially studied at a specific lipid/blood ratio, as an initial screening study. Following that, a more systematic evaluation of the effect of: (i) liposome surface PEGylation; (ii) vesicle size and (iii) arsonolipid incorporation in the vesicles lipid membrane was performed, at different lipid/blood ratios. with lauric (R = C 11 H 27 ) and palmitic (R = C 15 H 31 ) side chain respectively, were synthesized and characterized, as described in detail before [8] [9] [10] [11] and re-investigated recently 12 by Professor P. V. Ioannou (Department of Chemistry, University of Patras, Greece), and kindly provided to us.
MATERIALS AND METHODS

Reagents
Egg L--phosphatidylcholine [PC] (grade 1), 1,2- dipalmitoyl-sn-glycero-3-phosphocholine [DPPC] (synthetic,grade 1)
Liposome Compositions Tested
Liposomes composed of different phospholipids or phospholipid mixtures, referred to as conventional liposomes [CON] herein, were prepared (see Table I 
Preparation of Liposomes
ARSL were prepared by the "one-step" method, as described previously. 2 3 In brief, lipids (after removing the organic solvents with a nitrogen stream) were mixed with 5 mM phosphate buffer (pH 7.4) and 20 mM NaCl and magnetically stirred vigorously on a hot plate for 4 h at 70-80 C. The one step procedure has been demonstrated to produce oligolamellar or multilamellar (MLV) ARSL vesicles. 2 In order to reduce liposome size, and prepare sonicated ARSL, SUV, the suspension was sonicated, using a Vibra-cell probe sonicator (Sonics and Materials, UK) equipped with a tapered tip, for at least two 5 min cycles, or until liposomal suspension became clear. Following sonication, the liposome suspensions were left to stand for 1 h at 65 C (or higher than the transition temperature of the lipid used in each case), in order to anneal any structural defects. Titanium fragments, multilamellar vesicles or liposomal aggregates were removed by centrifugation at 10,000 g for 10 min. CON multilamellar liposomes were prepared by the thin film hydration method. 13 In brief, the lipids (total 5 mg) were dissolved in a CHCl 3 /CH 3 OH 2:1 v/v mixture which was evaporated by rotor evaporation, on a 100 mL round bottomed flask, at 40 C, to form a thin lipid film. Complete removal of organic solvents was achieved by flashing the flask with nitrogen gas and then connecting to a vacuum pump for at least 5 h. Finally the thin film was hydrated by addition of 1 mL of 5 mM phosphate buffer (pH 7.4) and 20 mM NaCl, at room temperature or at a temperature above the lipid transition temperature (whichever is highest), and vigorous vortexing-bath sonication. For liposome size reduction, and preparation of small unilamellar vesicles (SUV), the same procedure as described above for ARSL, was followed. The lipid concentration of the liposome dispersions was measured by the Stewart colorimetric assay.
14 In this assay, phospholipids form a colored complex with ammonium ferrothiocyanate (OD 485 nm) that is extracted with chloroform. Lipid concentration in samples is calculated on the basis of a standard curve prepared with known amount of each phospholipid. After measurement, the lipid concentrations of the liposome dispersions were adjusted at the desired value for haemolysis determination.
Liposome Characterization
Liposomes were characterized by measuring size by DLS (dynamic light spectroscopy) with a Malvern Zetasizer 5000 (Malvern, UK), as described before. 15 In brief, liposome dispersions were diluted with filtered TBS pH 7.40 and sized immediately. Vesicle electrophoretic mobility was measured at 25 C (Zetasizer 5000 Malvern Instruments, UK), after diluting the vesicle dispersion with filtered PBS pH 7.40. Zeta potentials of the dispersions were calculated (by application of the Helmholtz-Smolowkovski equation).
Measurement of Haemolysis
A simple technique usually applied for material-induced haemolysis evaluation, 1 was used. In brief, after 1 h of blood-material or RBC suspension-material mixture incubation under static conditions, the samples were centrifuged (for erythrocyte precipitation) and the haemolysis index was determined by the following formula:
The positive control (PosCon) is the value obtained after distilled water/blood incubation and the negative control (NegCon) is the value obtained after physiological saline/blood incubation. Blood was drawn from consenting human volunteers, placed into citrated test tubes (CTAD, Diagnostica Stago, France) and subsequently centrifuged at 5000 rpm for 10 min in order to separate erythrocytes from plasma.
In each case 100 l of CON or ARSL dispersion (after adjusting the lipid concentration of the dispersion) was mixed with 900 l of red blood cell suspension. These were gently mixed and incubated at room temperature for 1 h. After this, the mixture was mixed with 4 mL of physiological saline (0.9% w/v NaCl) and centrifuged at 10000 rpm for 15 min in order for erythrocytes to precipitate. The supernatant's optical density at 540 nm was measured by a Shimatzu mini 1240 UV-VIS spectrophotometer, and the % haemolysis was calculated by the equation presented above.
RESULTS AND DISCUSSION
Liposome Properties
The mean diameters and zeta-potential values measured for the various liposome types evaluated are presented in Table II 
Liposome Induced Haemolysis
The haemolysis (%) induced by the various liposome types evaluated initially, are presented in Figure 2 . As seen, in all cases the haemolysis induced by CON liposomes is always below 1%; oppositely, the ARSL tested induce higher haemolysis, especially the PEGylated ARSL composition. Indeed, sample 11 resulted in 7.09 ± 0.16 percent haemolysis, which was significantly higher (p < 0.01) than the haemolysis caused by all other liposome types evaluated; both CON liposomes (between 0.44 and 1.17% haemolysis) as well as ARSL (between 0.69 and 1.07% haemolysis). When comparing the haemolysis caused by ARSL (9, 10 and 11) with the equivalent compositions of CON liposomes (2, 7 and 2, respectively), in all cases of ARSL that contain the C 16 arsonolipid, ARSL are more haemolytic and the differences are statistically significant (at p = 0 05). Thereby, it seems that the presence of C 16 arsonolipids in the liposome membrane results in enhanced haemolytic activity, which is not the case for C 12 arsonolipid, at least at the specific lipid concentration tested. Interestingly, between the different lipid compositions of CON liposomes tested, the PC/Chol 1:1 liposomes resulted in highest haemolysis. The slight increase in the haemolysis percent caused by the liposomes with highest Chol content (50 mol%) may be attributed to the fact that the concentration of total lipid is higher (since Chol, is not measured by the Stewart assay) in this case (compared to the other liposomes evaluated in the initial study), which means that more vesicles were present in the same volume of blood, in this case.
The significantly higher (compared to the other liposome types evaluated) haemolytic activity caused by the PEGylated ARSL evaluated initially (Fig. 2 ) and the slightly higher haemolysis caused by the C 16 nonPegylated ARSL, compared to the CON liposomes (with 33 mol% Chol), prompted us to evaluate the effect of arsonolipid incorporation (in liposomes) and PEGylation on haemolysis, more systematically. Additionally, since liposome size reduction may result in higher haemolysis, due to surface area increase, as suggested before, 1 we decided to also evaluate the effect of vesicle size. Thereby, MLV and SUV ARSL vesicles composed of C 16 Ars, DSPC and Chol that were recently found to be very stable and were evaluated for in vivo distribution and in vitro anticancer activity were tested for their haemolytic activity at various lipid concentrations. Additionally, PEGylated (with 8 mol% DSPE-PEG2000 lipid), MLV and SUV ARSL were tested, in order to measure the effect of ARSL PEGylation on erythrocyte haemolysis. Furthermore, CON liposomes with the same lipid compositions but without Ars in their membrane were also tested at the same concentration range, as control liposomes.
The results of these later studies are presented in Figures 3 and 4. From Figure 3 , it is seen that arsonolipid-inclusion in the liposome membranes has a profound effect on the vesicle induced haemolysis, when high lipid concentrations are incubated with blood (high lipid/erythrocyte ratio). This is the case irrespective of vesicle size as observed for SUV liposomes (top graph) as well as MLV liposomes (bottom graph). The points which correspond to the haemolysis induced by the ARSL, in the graphs, were not connected in order to avoid misinterpretation of the experimental results, since there are no data points between the 0.18 and 0.6 mg/mL concentration values. In fact, when the haemolysis percent calculated for the PEGylated arsonoliposomes (sample 11 in the initial study performed, as presented in Fig. 1 ) is considered (included as a blue hollow square in the top graph of Fig. 3) , it becomes obvious that the haemolytic activity of the arsonoliposomes increases sharply when the lipid (total lipid) concentration in blood is higher than 0.3 mg/mL. From Figure 3 the effect of coating ARSL surface with PEG molecules on vesicle-induced-haemolysis becomes obvious; by comparing the solid and hollow squares for SUV ARSL (top graph) as well as MLV ARSL (bottom graph).
As stated above, the effect of arsonolipid on haemolysis is profound, regardless of the liposome size. Nevertheless, when comparing the top and bottom graph of Figure 3 , it is observed that vesicle size has also a profound effect on the haemolytic activity of ARSL, since the haemolysis values calculated for the SUV are 29 and 90 percent for non-PEGylated and PEGylated ARSL, respectively, and the corresponding values for the same MLV ARSL are approx. 15 and 35 percent.
In Figure 4 , the effect of PEGylation and vesicle size on the haemolytic activity of liposomes is presented separately for the ARSL (top graph) and the CON liposomes (bottom graph). It is observed (Fig. 4 top graph) that for ARSL the effect of PEGylation on vesicle haemolytic activity is higher compared to that of vesicle size, and in both cases the differences are significant only at the highest lipid concentration tested (0.6 mg lipid/mL of blood).
For the CON liposomes (Fig. 4, bottom graph) , although PEGylation is demonstrated to have a significant effect on MLV liposome haemolytic activity (slight increase) when the liposomes are small (SUV with increased surface area) PEGylation does not have an effect on vesicle-induced haemolysis (differences are not significant at p = 0.05). In that case surface area seems to be the predominant parameter. 
Discussion
The haemolytic activity of CON and arsonolipid containing liposomes (ARSL), SUV and MLV, without or with surface PEGylation was evaluated.
As seen by the results of both, the initial and the follow-up study performed (Figs. 2-4) haemolytic activity of CON liposomes (which are composed only by phospholipids), is minimum, even when extremely high lipid concentrations (in respect to concentration which may be reached after in vivo administration of liposomal formulations to humans) are incubated with erythrocytes. However, the situation is not the same with ARSL, especially the ones that contain C 16 arsonolipid. Furthermore ARSL haemolytic activity is dramatically enhanced by vesicle surface PEGylation and vesicle size reduction. Although, from a practical point of view, such high concentrations may not be compatible with potential administration of arsonoliposomes as drug carriers for therapeutic applications (due to the high dilutions in the large blood volume); from a theoretical point of view it is interesting to provide explanations for the effects demonstrated. In this respect, the lower haemolytic activity of ARSL that contain the C 12 arsonolipid, compared to those with the same lipid composition but with C 16 arsonolipid, can be explained by potential blocking or masking of the As polar head group of the arsonolipid (which is responsible for the haemolytic activity 6 7 ) by the phospholipid used in the membrane (PC, with mean acyl chain of 16 C atoms) in the case of C 12 ARSL. In fact, it is well known that the construction of liposomes with different lipid compositions can be used as a method to reduce the haemolytic activity in the case of ether lipids, by masking the ether lipid and thus reducing the haemolytic activity of the lipidic formulation. 16 Additionally, lipid coating has been used as a method to reduce blood toxicity of compounds in the past, 17 18 while the haemolytic and sphingomyelin-hydrolyzing activities of the enzyme sphingomyelinase toward intact bovine erythrocyte membrane were completely abolished by modification with ss-PEG. 19 In the case of ARSL composed of C 16 , size reduction resulted in a considerable increase of their haemolytic activity, although a similar increase was not noticed in the case of the CON liposomes tested (Fig. 4) . This indicates that the increased haemolysis, in the case of the sonicated ARSL cannot be-at least totally-attributed to the increase of vesicle surface area. Especially when the differences in size between MLV and SUV CON and ARSL vesicles is considered (Table II) it is evident that the increase in surface area (when moving from MLV to SUV) is minimum in the case of ARSL (compared to CON vesicles). Nevertheless, there is a possibility that the nonsonicated ARSL surface area is dramatically decreased due to aggregation, which was previously demonstrated to occur rapidly, for such vesicles. 20 Another possible explanation for the vast increase of haemolytic activity when moving from non-sonicated (MLV) to sonicated (SUV) ARSL, can be the different lipid packing in the lipid membrane bilayer, between the two vesicle types. Indeed, when the larger size of the arsonolipid headgroup is considered, it is logical to assume that a higher proportion of the arsonolipid will be in the outer lipid membrane of the bilayer since due to the larger diameter of the outer bilayer, it will be able to accommodate more arsonolipid molecules. Thereby, more As will be readily available for interaction with erythrocytes in the case of sonicated vesicles. Furthermore, most possibly, the larger membrane curvature of the sonicated ARSL, is another driving force that "moves" more arsonolipid molecules to the outer layer of the bilayer.
As observed by the experimental results of this study (Fig. 4) ARSL PEGylation resulted in a huge increase of their haemolytic activity, especially in the case of the sonicated ARSL studied. Such an effect was not observed for the CON vesicle types studied; in fact the case of the SUV CON liposomes, PEGylation had no effect on haemolytic activity. This result strengthens the above mentioned hypothesis, about the implications of ARSL aggregation and vesicle total surface area on their haemolytic activity. It is indeed well known, 21 22 that PEGylation abolishes the tendency of sonicated ASRL to aggregate and fuse into larger particles when incubated in presence of Ca 2+ ions, at concentrations relevant to those present in human blood.
CONCLUDING REMARKS
From a practical point of view the results of this study suggest that at the normal lipid concentration one expects to have in human blood after intravenous administration of a liposomal drug formulation or drug delivery system (100 mg lipid amount diluted in 4 L blood would give a concentration of 0.025 mg lipid/ml blood), both CON liposomes and ARSL with various compositions are safe to use. Indeed, the haemolysis values measured in such conditions were always below 1-2%, which is in the measurement error range. In the case of ARSL, especially PEGylated ones that contain the C 16 arsonolipid, high arsonolipid concentrations should be avoided for administration in the blood.
